M K PROTEINS

Date: 13.08.2026

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India
Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai – 400051
NSE SYMBOL: MKPL

Subject: Outcome of the Board Meeting held today i.e. on 13th August, 2026

Dear Sir/Madam,

With reference to the above, we hereby submit / inform that the Board of Directors ("the Board") of the Company at its meeting held today i.e. on 13th August, 2026:

1. approved the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2026.
   The said Un-Audited Financial Results prepared in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 together with the Limited Review Report (LRR) are enclosed. These results are also being uploaded on the Company's website at www.mkproteins.in.

2. took note of the resignation submitted by Ms. Laxmi Mandal (DIN: 05287716), Independent Director of the Company on 12th August 2026. The disclosure as required under Regulation 30 read with Para A(7B) of Part A of Schedule III of SEBI (LODR) Regulation, 2015 is already submitted to the stock exchanges.

The meeting of the Board of Directors commenced at 03:30 P.M. and concluded at 04:30 P.M.

You are requested to take the same on your record.

Thanking you,

Yours Faithfully,
FOR M K PROTEINS LIMITED

NEHA AGGARWAL Digitally signed by NEHA AGGARWAL Date: 2026.08.13 16:37:02 +05'30'

Neha Aggarwal
Company Secretary cum Compliance Officer

SUBHASH SAJAL & ASSOCIATES
Chartered Accountants
A Peer Reviewed Firm

1766, New Christian Colony,
Near Civil Hospital,
Jagadhri – 135003
M: 94166-84636, 98962-57600
Email: smittalca504@gmail.com
smittalca@rediffmail.com

Limited Review Report on Standalone Quarterly and year to date financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To,
The Board of Directors,
M. K. Proteins Limited

1. We have audited the accompanying statement of unaudited quarterly standalone financial results of **M. K. Proteins Limited** ("the Company") for the quarter ended June 30, 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (hereafter referred to as "the Regulations"), to the Stock Exchange.

2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, interim financial reporting (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and read with SEBI Circular No. CIR/CFD/FAC/62/2076 dated July 05, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these Financial Statements based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited quarterly Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies [Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Yamunanagar

Date: 13th August 2026

For Subhash Sajal and Associates
Chartered Accountants
Firm Registration No. 018178N

Subhash Sajal & Associates
Chartered Accountants
FRN: 018178N
Jagadhri

CA SAJAL MITTAL
(PARTNER)
Membership No.: 576124
UDIN: 26576124GJDJMB5031

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01021

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(Rs. In Lacs)

		QUARTER ENDED			YEAR ENDED	
		30-06-2026 (UNAUDITED)	31-03-2026 (AUDITED)	30-06-2025 (UNAUDITED)	31-03-2026 (AUDITED)	31-03-2025 (AUDITED)
1.	**Revenue**					
a)	Revenue from Operation (Net)	11516.12	14594.06	11494.60	38287.52	26770.60
b)	Other Income	0.00	11.80	0.00	25.94	47.66
	Sub-Total "1"	11516.12	14605.86	11494.60	38313.46	26818.26
2.	**Expenditure**					
a)	Cost of Material Consumed	9087.62	9651.40	8770.74	28648.84	16674.36
b)	Purchase of Stock-in-Trade	1234.55	1991.87	1688.76	7369.24	5149.41
c)	Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	346.27	1675.69	146.31	(717.06)	2146.27
d)	Employees Benefits Expenses	78.44	110.96	53.70	302.77	274.52
e)	Manufacturing, Operating and Other Expenses	517.78	914.38	284.07	1541.98	1282.93
f)	Finance Costs	51.94	79.03	70.16	185.20	110.50
g)	Depreciation and Amortization Expenses	14.78	10.79	10.35	43.63	35.17
	Sub-Total "2"	11331.38	14434.12	11024.09	37374.60	25673.16
3	Profit/(Loss) before Exceptional, Extraordinary items and Tax [1 – 2]	184.74	171.74	470.51	938.86	1145.10
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00
5	Profit/(Loss) before Extraordinary items and Tax [3 – 4]	184.74	171.74	470.51	938.86	1145.10
6	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before Tax [5 – 6]	184.74	171.74	470.51	938.86	1145.10
8	**Tax Expenses**					
a)	Provision for Current Tax	45.93	57.26	118.15	246.79	301.86
b)	Provision for Deferred Tax Liability/(Adjustment)	0.57	0.65	1.04	5.21	3.50
c)	Prior Year Taxes	0.00	0.00	0.00	3.96	0.00
	Sub-Total "8"	46.50	57.91	119.19	255.96	305.36
9	Profit/(Loss) for the Period from continuing operations [7 - 8]	138.24	113.83	351.32	682.90	839.74
10	Profit/(Loss) for the period from Discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00
11	Tax expenses of Discontinuing operations	0.00	0.00	0.00	0.00	0.00
12	Profit/(Loss) from Discontinuing operations (After Tax) [10 – 11]	0.00	0.00	0.00	0.00	0.00
13	Profit/(Loss) for the period [9 + 12]	138.24	113.83	351.32	682.90	839.74
14	**Other Comprehensive Income net of taxes**					
a)	(i) Amount of items that will not be reclassified to profit and loss	0.00	0.72	0.00	0.72	(1.51)
	(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	0.18	0.00	0.18	(0.38)
b)	(i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
	Sub- Total "14"	0.00	0.54	0.00	0.54	(1.13)
15	Total comprehensive Income for the Period [13 + 14]	138.24	114.37	351.32	683.44	838.61

16	**Earnings per share (refer Note 7)**					
a)	Earnings per Equity Share for continuing operations					
	Basic earnings/(Loss) per share from continuing operations	0.04	0.03	0.09	0.18	0.22
	Diluted earning/(Loss) per share from continuing operations	0.04	0.03	0.09	0.18	0.22
b)	Earnings per Equity Share for discontinuing operations					
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00
c)	Earnings per Equity Share					
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.04	0.03	0.09	0.18	0.22
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.04	0.03	0.09	0.18	0.22
17	**Details of Equity Share Capital**					
	Paid-up Equity Share Capital	3753.72	3753.72	3753.72	3753.72	3753.72
	Face value of Equity Share Capital	1	1	1	1	1
18	Other Equity [Reserves]	-	-	-	3876.30	3192.86

Note:

1. The above mentioned un-audited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th August, 2026.
2. Previous period/year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
3. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.
4. The above results have been reviewed by the Statutory Auditor as required under regulation 33 of SEBI (Listing Obligations & Disclosure Requirements, 2015).

Place: Ambala

Dated: 13/08/2026

For and on behalf of the board

(Parmod Kumar)
Managing Director
DIN: 00126965